Molnupiravir

Background

Molnupiravir, an oral antiviral, was initially authorized for mild-to-moderate COVID-19 cases. It has potential as a long COVID treatment due to its ability to introduce mutations in the viral RNA, leading to viral replication errors that can help clear residual virus from the body.

Mechanism of Action

• Molnupiravir: Works as a mutagenic ribonucleoside analog, causing errors in the viral RNA replication process. This error-prone replication reduces the viability of the virus (Molnupiravir Study).

Pros and Cons

• Pros: Orally administered, making it accessible; may effectively reduce viral load in cases with persistent SARS-CoV-2.
• Cons: Limited data on long-term effects; potential mutagenic risks, particularly not recommended during pregnancy.

References

1. Molnupiravir Study

‍